<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DDAVP- desmopressin acetate tablet </strong><br>sanofi-aventis U.S. LLC<br></p></div>
<h1>DDAVP<span class="Sup">®</span> Tablets<br>(desmopressin acetate)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="Bold">DDAVP<span class="Sup">®</span> Tablets</span> (desmopressin acetate) are a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. It is chemically defined as follows:</p>
<p>Mol. Wt. 1183.34	        Empirical Formula: C<span class="Sub">46</span>H<span class="Sub">64</span>N<span class="Sub">14</span>O<span class="Sub">12</span>S<span class="Sub">2</span> • C<span class="Sub">2</span>H<span class="Sub">4</span>O<span class="Sub">2</span> • 3H<span class="Sub">2</span>O</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bb9b8d5-eed6-45cb-b1b9-e43d3ee6fecd&amp;name=ddavp-01.jpg"></div>
<p>1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate.</p>
<p><span class="Bold">DDAVP Tablets</span> contain either 0.1 or 0.2 mg desmopressin acetate. Inactive ingredients include: lactose, potato starch, magnesium stearate and povidone.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="Bold">DDAVP Tablets</span> contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>Central <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h2>
<p class="First">Dose response studies in patients with <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> have demonstrated that oral doses of 0.025 mg to 0.4 mg produced clinically significant antidiuretic effects. In most patients, doses of 0.1 mg to 0.2 mg produced optimal antidiuretic effects lasting up to eight hours. With doses of 0.4 mg, antidiuretic effects were observed for up to 12 hours; measurements beyond 12 hours were not recorded. Increasing oral doses produced dose dependent increases in the plasma levels of DDAVP (desmopressin acetate).</p>
<p>The plasma half-life of DDAVP followed a monoexponential time course with t<span class="Sub">1/2</span> values of 1.5 to 2.5 hours which was independent of dose.</p>
<p>The bioavailability of DDAVP oral tablets is about 5% compared to intranasal DDAVP, and about 0.16% compared to intravenous DDAVP. The time to reach maximum plasma DDAVP levels ranged from 0.9 to 1.5 hours following oral or intranasal administration, respectively. Following administration of <span class="Bold">DDAVP Tablets</span>, the onset of antidiuretic effect occurs at around 1 hour, and it reaches a maximum at about 4 to 7 hours based on the measurement of increased urine <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span>.</p>
<p>The use of <span class="Bold">DDAVP Tablets</span> in patients with an established diagnosis will result in a reduction in urinary output with an accompanying increase in urine <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span>. These effects usually will allow resumption of a more normal life style, with a decrease in <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span> and <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>.</p>
<p>There are reports of an occasional change in response to the intranasal formulations of DDAVP (DDAVP Nasal Spray and DDAVP Rhinal Tube). Usually, the change occurred over a period of time greater than six months. This change may be due to decreased responsiveness, or to shortened duration of effect. There is no evidence that this effect is due to the development of binding antibodies, but may be due to a local inactivation of the peptide. No lessening of effect was observed in the 46 patients who were treated with <span class="Bold">DDAVP Tablets</span> for 12 to 44 months and no serum antibodies to desmopressin were detected.</p>
<p>The change in structure of arginine vasopressin to desmopressin acetate resulted in less vasopressor activity and decreased action on visceral smooth muscle relative to enhanced antidiuretic activity. Consequently, clinically effective antidiuretic doses are usually below the threshold for effects on vascular or visceral smooth muscle. In the four long-term studies of <span class="Bold">DDAVP Tablets</span>, no increases in blood pressure in 46 patients receiving <span class="Bold">DDAVP Tablets</span> for periods of 12 to 44 months were reported.</p>
<p>In one study, the pharmacodynamic characteristics of <span class="Bold">DDAVP Tablets</span> and intranasal formulation were compared during an 8-hour dosing interval at steady state. The doses administered to 36 hydrated (water loaded) healthy male adult volunteers every 8 hours were 0.1, 0.2, 0.4 mg orally and 0.01 mg intranasally by rhinal tube. The results are shown in the following table:</p>
<table width="75%">
<col align="center">
<col align="center">
<col align="center">
<thead>
<tr class="First"><th class="Botrule Lrule Rrule" align="center" colspan="3">Mean Changes from Baseline (SE) in Pharmacodynamic Parameters in Normal Healthy Adult Volunteers</th></tr>
<tr class="Last">
<th class="Lrule" align="center" valign="top">Treatment</th>
<th class="Lrule" align="center">Total Urine Volume in mL</th>
<th class="Lrule Rrule" align="center">Maximum Urine <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">Osmolality</span> in mOsm/kg</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">(SE) = Standard error of the mean</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="center">0.1 mg PO q8h</td>
<td class="Botrule Lrule" align="center">-3689.3 (149.6)</td>
<td class="Botrule Lrule Rrule" align="center">514.8 (21.9)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">0.2 mg PO q8h</td>
<td class="Botrule Lrule" align="center">-4429.9 (149.6)</td>
<td class="Botrule Lrule Rrule" align="center">686.3 (21.9)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">0.4 mg PO q8h</td>
<td class="Botrule Lrule" align="center">-4998.8 (149.6)</td>
<td class="Botrule Lrule Rrule" align="center">769.3 (21.9)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">0.01 mg IN q8h</td>
<td class="Botrule Lrule" align="center">-4844.9 (149.6)</td>
<td class="Botrule Lrule Rrule" align="center">754.1 (21.9)</td>
</tr>
</tbody>
</table>
<p>With respect to the mean values of total urine volume decrease and maximum urine <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> increase from baseline, the 90% confidence limits estimated that the 0.4 mg and 0.2 mg oral dose produced between 95% and 110% and 84% to 99% of pharmacodynamic activity, respectively, when compared to the 0.01 mg intranasal dose.</p>
<p>While both the 0.2 mg and 0.4 mg oral doses are considered pharmacodynamically similar to the 0.01 mg intranasal dose, the pharmacodynamic data on an inter-subject basis was highly variable and, therefore, individual dosing is recommended.</p>
<p>In another study in <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> patients, the pharmacodynamic characteristics of <span class="Bold">DDAVP Tablets</span> and intranasal formulations were compared over a 12-hour period. Ten fluid-controlled patients under age 18 were administered tablet doses of 0.2 mg and 0.4 mg, and intranasal doses of 0.01 mg and 0.02 mg.</p>
<table width="75%">
<col align="center">
<col align="center">
<col align="center">
<thead>
<tr class="First"><th class="Botrule Lrule Rrule" align="center" colspan="3">Mean Peak Pharmacodynamic Parameters (SD) in Pediatric and Adolescent <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span> Patients</th></tr>
<tr class="Last">
<th class="Lrule" align="center" valign="top">Treatment</th>
<th class="Lrule" align="center">Urine Volume in mL/min</th>
<th class="Lrule Rrule" align="center">Maximum Urine <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">Osmolality</span> in mOsm/kg</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">(SD) = Standard Deviation</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="center">0.01 mg IN</td>
<td class="Botrule Lrule" align="center">0.3 (0.15)</td>
<td class="Botrule Lrule Rrule" align="center">717.0 (224.63)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">0.02 mg IN</td>
<td class="Botrule Lrule" align="center">0.3 (0.25)</td>
<td class="Botrule Lrule Rrule" align="center">761.8 (298.82)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">0.2 mg PO</td>
<td class="Botrule Lrule" align="center">0.3 (0.12)</td>
<td class="Botrule Lrule Rrule" align="center">678.3 (147.91)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">0.4 mg PO</td>
<td class="Botrule Lrule" align="center">0.2 (0.15)</td>
<td class="Botrule Lrule Rrule" align="center">787.2 (73.34)</td>
</tr>
</tbody>
</table>
<p>All four dose formulations (0.01 mg IN, 0.02 mg IN, 0.2 mg PO and 0.4 mg PO) have a similar, pronounced pharmacodynamic effect on urine volume and urine <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span>. At two hours after study drug administration, mean urine volume was 4 mL/min and urine <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> was &gt;500 mOsm/kg. Mean plasma <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> remained relatively constant over the time course recorded (0 to 12 hours). A statistical separation from baseline did not occur at any dose or time point. In these patients, the 0.2 mg tablets and the 0.01 mg intranasal spray exhibited similar pharmacodynamic profiles as did the 0.4 mg tablets and the 0.02 mg intranasal spray formulation. In another study of adult <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> patients previously controlled on DDAVP intranasal spray, after one week of self-titration from spray to tablets, patients' <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> was controlled with 0.1 mg <span class="Bold">DDAVP Tablets</span> three times a day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>Primary <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">Nocturnal Enuresis</span></h2>
<p class="First">Two double-blind, randomized, placebo-controlled studies were conducted in 340 patients with primary <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">nocturnal enuresis</span>. Patients were 5-17 years old, and 72% were males. A total of 329 patients were evaluated for efficacy. Patients were evaluated over a two-week baseline period in which the average number of wet nights was 10 (range 4-14). Patients were then randomized to receive 0.2, 0.4, or 0.6 mg of DDAVP or placebo. The pooled results after two weeks are shown in the following table:</p>
<table width="75%">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<thead>
<tr class="First"><th class="Botrule Lrule Rrule" align="center" colspan="5">Response to DDAVP and Placebo at Two Weeks of Treatment Mean (SE) Number of Wet Nights/2 Weeks</th></tr>
<tr class="Last">
<th class="Lrule" align="center"></th>
<th class="Lrule" align="center">Placebo<br> (n = 85)</th>
<th class="Lrule" align="center">0.2 mg/day<br>(n = 79)</th>
<th class="Lrule" align="center">0.4 mg/day<br>(n = 82)</th>
<th class="Lrule Rrule" align="center">0.6 mg/day<br>(n = 83)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left">Baseline</td>
<td class="Botrule Lrule" align="center">10 (0.3)</td>
<td class="Botrule Lrule" align="center">11 (0.3)</td>
<td class="Botrule Lrule" align="center">10 (0.3)</td>
<td class="Botrule Lrule Rrule" align="center">10 (0.3)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Reduction from Baseline</td>
<td class="Botrule Lrule" align="center">1 (0.3)</td>
<td class="Botrule Lrule" align="center">3 (0.4)</td>
<td class="Botrule Lrule" align="center">3 (0.4)</td>
<td class="Botrule Lrule Rrule" align="center">4 (0.4)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Percent Reduction from Baseline</td>
<td class="Botrule Lrule" align="center">10%</td>
<td class="Botrule Lrule" align="center">27%</td>
<td class="Botrule Lrule" align="center">30%</td>
<td class="Botrule Lrule Rrule" align="center">40%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">p-value vs placebo</td>
<td class="Botrule Lrule" align="center">----</td>
<td class="Botrule Lrule" align="center">&lt;0.05</td>
<td class="Botrule Lrule" align="center">&lt;0.05</td>
<td class="Botrule Lrule Rrule" align="center">&lt;0.05</td>
</tr>
</tbody>
</table>
<p>Patients treated with <span class="Bold">DDAVP Tablets</span> showed a statistically significant reduction in the number of wet nights compared to placebo-treated patients. A greater response was observed with increasing doses up to 0.6 mg.</p>
<p>In a six month, open-label extension study, patients completing the placebo-controlled studies were started on 0.2 mg/day DDAVP, and the dose was progressively increased until the optimal response was achieved (maximum dose 0.6 mg/day). A total of 230 patients were evaluated for efficacy; the average number of wet nights/2 weeks during the untreated baseline period was 10 (range 4-14), and the average duration (SD) of treatment was 4.2 (1.8) months. Twenty-five (25) patients (11%) achieved a complete or near complete response (≤2 wet nights/2 weeks) and did not require titration to the 0.6 mg/day dose. The majority of patients (198 of 230, 86%) were titrated to the highest dose. When all dose groups were combined, 128 (56%) showed at least a 50% reduction from baseline in the number of wet nights/2 weeks, while 87 (38%) patients achieved a complete or near complete response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Clin_Pharm_Human"></a><a name="section-2.3"></a><p></p>
<h2>Human Pharmacokinetics</h2>
<p class="First">DDAVP is mainly excreted in the urine. A pharmacokinetic study conducted in healthy volunteers and patients with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (n=24, 6 subjects in each group) receiving single dose desmopressin acetate (2mcg) injection demonstrated a difference in DDAVP terminal half-life. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (See <span class="Bold"><a href="#Contra">CONTRAINDICATIONS</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Central <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h2>
<p class="First"><span class="Bold">DDAVP Tablets</span> are indicated as antidiuretic replacement therapy in the management of central <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> and for the management of the temporary <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> following head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or surgery in the pituitary region. DDAVP is ineffective for the treatment of <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span>.</p>
<p>Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to DDAVP can be monitored by measuring urine volume and <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Primary <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">Nocturnal Enuresis</span></h2>
<p class="First"><span class="Bold">DDAVP Tablets</span> are indicated for the management of primary <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">nocturnal enuresis</span>. DDAVP may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Contra"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">DDAVP Tablets</span> are contraindicated in individuals with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to desmopressin acetate or to any of the components of <span class="Bold">DDAVP Tablets</span>.</p>
<p>DDAVP is contraindicated in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (defined as a creatinine clearance below 50ml/min).</p>
<p>DDAVP is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> or a history of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">1. Very rare cases of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> have been reported from world-wide postmarketing experience in patients treated with DDAVP (desmopressin acetate). DDAVP is a potent antidiuretic which, when administered, may lead to <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> and/or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. Unless properly diagnosed and treated <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> can be fatal. Therefore, fluid restriction is recommended and should be discussed with the patient and/or guardian. Careful medical supervision is required.</p>
<p>2. When DDAVP Tablets are administered, in particular in pediatric and geriatric patients, fluid intake should be adjusted downward to decrease the potential occurrence of <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.(See <span class="Bold"><a href="#Pediatric_Use">PRECAUTIONS, Pediatric Use</a></span> and <span class="Bold"><a href="#Prec_Ger">Geriatric Use</a></span>.) All patients receiving DDAVP therapy should be observed for the following signs or symptoms associated with <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, decreased serum sodium, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, depressed reflexes, loss of appetite, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> and abnormal mental status such as <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, decreased consciousness and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. Severe symptoms may include one or a combination of the following: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>. Particular attention should be paid to the possibility of the rare occurrence of an extreme decrease in plasma <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> that may result in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> which could lead to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
<p>3. DDAVP should be used with caution in patients with habitual or <span class="product-label-link" type="condition" conceptid="4049477" conceptname="Psychogenic polydipsia">psychogenic polydipsia</span> who may be more likely to drink excessive amounts of water, putting them at greater risk of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Intranasal formulations of DDAVP at high doses and DDAVP Injection have infrequently produced a slight elevation of blood pressure which disappears with a reduction of dosage. Although this effect has not been observed when single oral doses up to 0.6 mg have been administered, the drug should be used with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease, because of a possible <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>.</p>
<p>DDAVP should be used with caution in patients with conditions associated with fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, such as <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disorders</span> because these patients are prone to <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. Rare severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been reported with DDAVP. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has been reported rarely with intravenous and intranasal administration of DDAVP but not with <span class="Bold">DDAVP Tablets.</span></p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-6.2"></a><p></p>
<h2>Laboratory Tests</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<h3>Central <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h3>
<p class="First">Laboratory tests for monitoring the patient with central <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> or post-surgical or head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>-related <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> include urine volume and <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span>. In some cases, measurements of plasma <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> may be useful.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Although the pressor activity of DDAVP is very low compared to its antidiuretic activity, large doses of <span class="Bold">DDAVP Tablets</span> should be used with other pressor agents only with careful patient monitoring. The concomitant administration of drugs that may increase the risk of <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> with <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, NSAIDs, lamotrigine and carbamazepine) should be performed with caution.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.4"></a><p></p>
<h2>Carcinogenicity, Mutagenicity, Impairment of Fertility</h2>
<p class="First">Studies with DDAVP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5.1"></a><p></p>
<h3>Category B</h3>
<p class="First">Fertility studies have not been done. Teratology studies in rats and rabbits at doses from 0.05 to 10 mcg/kg/day (approximately 0.1 times the maximum systemic human exposure in rats and up to 38 times the maximum systemic human exposure in rabbits based on surface area, mg/m<span class="Sup">2</span>) revealed no harm to the fetus due to DDAVP<span class="Bold"><span class="Sup">®</span></span> (desmopressin acetate). There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p>Several publications where desmopressin acetate was used in the management of <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> during pregnancy are available; these include a few anecdotal reports of congenital anomalies and low birth weight babies. However, no causal connection between these events and desmopressin acetate has been established. A fifteen year Swedish epidemiologic study of the use of desmopressin acetate in pregnant women with <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> found the rate of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> to be no greater than that in the general population; however, the statistical power of this study is low. As opposed to preparations containing natural hormones, desmopressin acetate in antidiuretic doses has no uterotonic action and the physician will have to weigh the possible therapeutic advantages against the possible risks in each case.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">There have been no controlled studies in nursing mothers. A single study in postpartum women demonstrated a marked change in plasma, but little if any change in assayable DDAVP in breast milk following an intranasal dose of 0.01 mg.</p>
<p>It is not known whether the drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DDAVP is administered to nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Pediatric_Use"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.7.1"></a><p></p>
<h3>Central <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h3>
<p class="First"><span class="Bold">DDAVP Tablets</span> (desmopressin acetate) have been used safely in pediatric patients, age 4 years and older, with <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> for periods up to 44 months. In younger pediatric patients the dose must be individually adjusted in order to prevent an excessive decrease in plasma <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> leading to <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and possible <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>; dosing should start at 0.05 mg (1/2 of the 0.1 mg tablet). Use of <span class="Bold">DDAVP Tablets</span> in pediatric patients requires careful fluid intake restrictions to prevent possible <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>. Fluid restriction should be discussed with the patient and/or guardian. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.7.2"></a><p></p>
<h3>Primary <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">Nocturnal Enuresis</span></h3>
<p class="First"><span class="Bold">DDAVP Tablets</span> have been safely used in pediatric patients age 6 years and older with primary <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">nocturnal enuresis</span> for up to 6 months. Some patients respond to a dose of 0.2 mg; however, increasing responses are seen at doses of 0.4 mg and 0.6 mg. No increase in the frequency or severity of adverse reactions or decrease in efficacy was seen with an increased dose or duration. The dose should be individually adjusted to achieve the best results. Treatment with desmopressin for primary <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">nocturnal enuresis</span> should be interrupted during acute intercurrent illness characterized by fluid and/or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> (e.g., systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, recurrent <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>) or under conditions of extremely hot weather, vigorous exercise or other conditions associated with increased water intake.</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Prec_Ger"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of DDAVP Tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. DDAVP is contraindicated in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (defined as a creatinine clearance below 50ml/min).</p>
<p>(See <span class="Bold"><a href="#Clin_Pharm_Human">CLINICAL PHARMACOLOGY, Human Pharmacokinetics</a></span> and <span class="Bold"><a href="#Contra">CONTRAINDICATIONS</a></span>.)</p>
<p>Use of DDAVP Tablets in geriatric patients requires careful fluid intake restrictions to prevent possible <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>. Fluid restriction should be discussed with the patient. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Adverse_Reactions"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Infrequently, large doses of the intranasal formulations of DDAVP and DDAVP Injection have produced transient <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> and mild <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>. These symptoms have disappeared with reduction in dosage.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>Central <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h2>
<p class="First">In long-term clinical studies in which patients with <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> were followed for periods up to 44 months of <span class="Bold">DDAVP Tablet</span> therapy, transient increases in AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) no higher than 1.5 times the upper limit of normal were occasionally observed. Elevated AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) returned to the normal range despite continued use of <span class="Bold">DDAVP Tablets</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Primary <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">Nocturnal Enuresis</span></h2>
<p class="First">The only adverse event occurring in ≥3% of patients in controlled clinical trials with <span class="Bold">DDAVP Tablets</span> that was probably, possibly, or remotely related to study drug was <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (4% DDAVP, 3% placebo).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Other</h2>
<p class="First">The following adverse events have been reported; however their relationship to DDAVP has not been established: <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>-<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. See <span class="Bold"><a href="#Warnings">WARNINGS</a></span> for the possibility of <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p><span class="Bold">Post Marketing:</span> There have been rare reports of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremic</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> associated with concomitant use with the following medications: oxybutinin and imipramine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"> Signs of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, continuing <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, problems with passing urine and rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. (See <span class="Bold"><a href="#Warnings">WARNINGS</a></span>.) In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the dose should be reduced, frequency of administration decreased, or the drug withdrawn according to the severity of the condition. There is no known specific antidote for DDAVP. The patient should be observed and treated with appropriate symptomatic therapy.</p>
<p>An oral LD<span class="Sub">50</span> has not been established. Oral doses up to 0.2 mg/kg/day have been administered to dogs and rats for 6 months without any significant drug-related toxicities reported. An intravenous dose of 2 mg/kg in mice demonstrated no effect.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Central <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h2>
<p class="First">The dosage of <span class="Bold">DDAVP Tablets</span> must be determined for each individual patient and adjusted according to the diurnal pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover. Patients previously on intranasal DDAVP therapy should begin tablet therapy twelve hours after the last intranasal dose. During the initial dose titration period, patients should be observed closely and appropriate safety parameters measured to assure adequate response. Patients should be monitored at regular intervals during the course of <span class="Bold">DDAVP Tablet</span> therapy to assure adequate antidiuretic response. Modifications in dosage regimen should be implemented as necessary to assure adequate water turnover. Fluid restriction should be observed. (See <span class="Bold"><a href="#Warnings">WARNINGS</a>, <a href="#Pediatric_Use">PRECAUTIONS, Pediatric Use</a></span> and <span class="Bold"><a href="#Prec_Ger">Geriatric Use</a></span>.) </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1.1"></a><p></p>
<h3>Adults and Children</h3>
<p class="First">It is recommended that patients be started on doses of 0.05 mg (1/2 of the 0.1 mg tablet) two times a day and individually adjusted to their optimum therapeutic dose. Most patients in clinical trials found that the optimal dosage range is 0.1 mg to 0.8 mg daily, administered in divided doses. Each dose should be separately adjusted for an adequate diurnal rhythm of water turnover. Total daily dosage should be increased or decreased in the range of 0.1 mg to 1.2 mg divided into two or three daily doses as needed to obtain adequate antidiuresis. See <span class="Bold"><a href="#Pediatric_Use">Pediatric Use</a></span> subsection for special considerations when administering desmopressin acetate to pediatric <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See <span class="Bold"><a href="#Clin_Pharm_Human">CLINICAL PHARMACOLOGY, Human Pharmacokinetics</a></span>, <span class="Bold"><a href="#Contra">CONTRAINDICATIONS</a></span>, and <span class="Bold"><a href="#Prec_Ger">PRECAUTIONS, Geriatric Use</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>Primary <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">Nocturnal Enuresis</span></h2>
<p class="First">The dosage of <span class="Bold">DDAVP Tablets</span> must be determined for each individual patient and adjusted according to response. Patients previously on intranasal DDAVP therapy can begin tablet therapy the night following (24 hours after) the last intranasal dose. The recommended initial dose for patients age 6 years and older is 0.2 mg at bedtime. The dose may be titrated up to 0.6 mg to achieve the desired response. Fluid restriction should be observed, and fluid intake should be limited to a minimum from 1 hour before desmopressin administration, until the next morning, or at least 8 hours after administration. (See <span class="Bold"><a href="#Warnings">WARNINGS</a>, <a href="#Pediatric_Use">PRECAUTIONS, Pediatric Use</a></span> and <span class="Bold"><a href="#Prec_Ger">Geriatric Use</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<table width="100%">
<col align="left" width="19%">
<col align="left" width="19%">
<col align="left" width="19%">
<col align="left" width="19%">
<col align="center" width="24%">
<thead><tr class="First Last">
<th class="Lrule" align="left">Strength</th>
<th class="Lrule" align="left">Size</th>
<th class="Lrule" align="left">NDC 0075-</th>
<th class="Lrule" align="left">Color</th>
<th class="Lrule Rrule" align="left">Markings</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left" valign="top">0.1 mg</td>
<td class="Botrule Lrule" align="left" valign="top">Bottle <br>of 100</td>
<td class="Botrule Lrule" align="left" valign="top">0016-00</td>
<td class="Botrule Lrule" align="left" valign="top">White</td>
<td class="Botrule Lrule Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bb9b8d5-eed6-45cb-b1b9-e43d3ee6fecd&amp;name=ddavp-02.jpg"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top">0.2 mg</td>
<td class="Botrule Lrule" align="left" valign="top">Bottle <br>of 100</td>
<td class="Botrule Lrule" align="left" valign="top">0026-00</td>
<td class="Botrule Lrule" align="left" valign="top">White</td>
<td class="Botrule Lrule Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bb9b8d5-eed6-45cb-b1b9-e43d3ee6fecd&amp;name=ddavp-03.jpg"></td>
</tr>
</tbody>
</table>
<p>Store at Controlled Room Temperature 20 to 25°C (68 to 77°F) [see USP]. Avoid exposure to excessive heat or light.</p>
<p>This product should be dispensed in a container with a child-resistant cap.</p>
<p><span class="Bold">Keep out of the reach of children.</span></p>
<p>U.S. Patent Nos. 5,500,413; 5,596,078; 5,674,850; 5,047,398; 5,763,407</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br><span class="Bold">sanofi-aventis U.S. LLC</span><br>Bridgewater, NJ  08807 USA<br>Revised July 2007</p>
<p>©2007 sanofi-aventis U.S. LLC</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 0.1mL Bottle Carton</h1>
<p class="First">NDC 0075-0016-00</p>
<p><span class="Bold">DDAVP<span class="Sup">®</span><br>
						Tablets</span><br><span class="Italics">desmopressin<br>acetate</span></p>
<p><span class="Bold">0.1</span>mg</p>
<p><span class="Bold">100 </span>Tablets</p>
<p><span class="Bold">sanofi aventis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 0.1mL Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bb9b8d5-eed6-45cb-b1b9-e43d3ee6fecd&amp;name=ddavp-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 0.2mL Bottle Carton</h1>
<p class="First">NDC 0075-0026-00</p>
<p><span class="Bold">DDAVP<span class="Sup">®</span><br>Tablets</span><br><span class="Italics">desmopressin <br>acetate</span></p>
<p><span class="Bold">0.2</span>mg</p>
<p><span class="Bold">100 </span>Tablets</p>
<p><span class="Bold">sanofi aventis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 0.2mL Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1bb9b8d5-eed6-45cb-b1b9-e43d3ee6fecd&amp;name=ddavp-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DDAVP 		
					</strong><br><span class="contentTableReg">desmopressin acetate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0075-0016</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Desmopressin Acetate</strong> (Desmopressin) </td>
<td class="formItem">Desmopressin</td>
<td class="formItem">0.1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, potato </strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Oval) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">0;1;36;AV</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0075-0016-00</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019955</td>
<td class="formItem">09/06/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DDAVP 		
					</strong><br><span class="contentTableReg">desmopressin acetate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0075-0026</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Desmopressin Acetate</strong> (Desmopressin) </td>
<td class="formItem">Desmopressin</td>
<td class="formItem">0.2 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">0;2;37;AV</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0075-0026-00</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019955</td>
<td class="formItem">09/06/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>sanofi-aventis U.S. LLC
							(824676584)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Ferring International Center SA</td>
<td class="formItem"></td>
<td class="formItem">481210362</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rechon Life Science AB</td>
<td class="formItem"></td>
<td class="formItem">775207769</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>594ad44c-9c5d-47ad-b596-f667476a6b2f</div>
<div>Set id: 1bb9b8d5-eed6-45cb-b1b9-e43d3ee6fecd</div>
<div>Version: 5</div>
<div>Effective Time: 20090901</div>
</div>
</div> <div class="DistributorName">sanofi-aventis U.S. LLC</div></p>
</body></html>
